Korean Pharma Highlights R&D Progress, 2020 Strategy At JPM
Obesity Emerges As Key Theme
Executive Summary
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.
You may also be interested in...
Changes Encourage Celltrion And Nan Fung To Bet On China Biosimilars Opportunity
Despite increasing competition, Celltrion has leapt into China's growing biosimilar market through a joint venture with Nan Fung, and another draw could lie in the biologics contract manufacturing potential in the country’s developing Greater Bay Area.
Hanmi Faces Another Licensee U-Turn, This Time Janssen On Obesity/Diabetes Drug
Janssen has returned the rights to an obesity/diabetes drug to originator Hanmi, after Phase II studies failed to achieve glycemic control targets and reflecting development difficulties in the sector. This is the fourth time for the Korean firm to face a U-turn of licensed out compounds.
Should Global Pharmas Focus More On Korean Partners?
PharmaVentures’ Adrian Dawkes talks about how COVID-19 will impact pharma deals going forward and how Korean firms in particular may be able to grab opportunities in the global arena.